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Abstract 
Although ellipticine (Elli) is an efficient anticancer agent, it exerts several adverse effects. One 
approach to decrease the adverse effects of drugs is their encapsulation inside a suitable 
nanocarrier, allowing targeted delivery to tumour tissue whereas avoiding healthy cells. We 
constructed a nanocarrier from apoferritin (Apo) bearing ellipticine, ApoElli, and subsequently 
characterized. The nanocarrier exhibits a narrow size distribution suggesting its suitability for 
entrapping the hydrophobic ellipticine molecule. Ellipticine was released from ApoElli into the 
water environment under pH 6.5, but only less than 20% was released at pH 7.4. The interaction 
of ApoElli with microsomal membrane particles containing cytochrome P450 (CYP) 
biotransformation enzymes accelerated the release of ellipticine from this nanocarrier making 
it possible to be transferred into this membrane system even at pH 7.4 and facilitating CYP-
mediated metabolism. Reactive metabolites were formed not only from free ellipticine, but also 
from ApoElli, and both generated covalent DNA adducts. ApoElli was toxic in UKF-NB-4 
neuroblastoma cells, but showed significantly lower cytotoxicity in non-malignant fibroblast 
HDFn cells. Ellipticine either free or released from ApoElli was concentrated in the nuclei of 
neuroblastoma cells, concentrations of which being significantly higher in nuclei of UKF-NB-
4 than in HDFn cells. In HDFn the higher amounts of ellipticine were sequestrated in 
lysosomes. The extent of ApoElli entering the nuclei in UKF-NB-4 cells was lower than that of 
free ellipticine and correlated with the formation of ellipticine-derived DNA adducts. Our study 
indicates that the ApoElli form of ellipticine seems to be a promising tool for neuroblastoma 
treatment. 
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glyceraldehyde 3-phosphate dehydrogenase; HDFn, neonatal human dermal fibroblasts; HPLC, 
high performance liquid chromatography; IMDM, Iscove’s modified Dulbecco’s medium; PEI, 
polyethylenimine; POR, NADPH:cytochrome P450 oxidoreductase; RAL, relative adduct 
labelling; RBC, red blood cells; RES, reticuloendothelial system; SCARA5, scavenger receptor 
class A member 5; TEM, transmission electron microscopy; TLC, thin-layer chromatography; 
TfR1. transferrin receptor 1. 
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1. Introduction 
Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole, Fig. 1) and its derivatives are 
efficient anticancer agents that function through multiple mechanisms participating in cell cycle 
arrest and initiation of apoptosis (Auclair, 1987; Garbett et al., 2004; Kizek et al., 2012; 
Stiborova and Frei, 2014; Stiborová et al., 2011; 2015a). The main reason for the interest in 
ellipticine and its derivatives for clinical purposes is their high efficacy against several types of 
cancer (Auclair, 1987; Garbett et al., 2004; Kizek et al., 2012; Stiborova and Frei, 2014; 
Stiborová et al., 2011; 2015a). The predominant mechanisms of ellipticine’s biological effects 
were proposed to be intercalation into DNA (Auclair, 1987; Garbett et al., 2004; Tmejova et 
al., 2014) and inhibition of topoisomerase II (Auclair, 1987; Garbett et al., 2004; Kizek et al., 
2012; Stiborova and Frei, 2014; Stiborová et al., 2011; 2015a). We also showed that this 
antitumor agent forms covalent DNA adducts after metabolic activation by cytochrome P450 
(CYP) enzymes and peroxidases (Stiborová et al., 2001, 2003a; 2003b; 2004; 2007a; 2007b; 
2008; 2012b; Kotrbová et al., 2011), suggesting an additional DNA-damaging effect of 
ellipticine. This DNA damage has been found to be the major mechanism of ellipticine’s 
antitumor activities (Stiborová et al., 2011; 2012b; 2014b; 2015a; Stiborova and Frei, 2014). 
Of the CYP enzymes, human CYP3A4 is the most active enzyme oxidizing ellipticine to 12-
hydroxy- and 13-hydroxyellipticine, the reactive metabolites that dissociate to ellipticine-12-
ylium and ellipticine-13-ylium which form two covalent DNA adducts (Fig. 1) (Stiborová et 
al., 2004; 2006; 2008; 2011; 2012a; 2012b; 2014b; 2015b). CYP3A4 also generates further 
metabolites such as 9-hydroxyellipticine, which is considered to be a detoxification metabolite 
as well as 7-hydroxyellipticine and ellipticine N2-oxide (both minor metabolites) (Stiborová et 
al., 2004; 2011; 2012a; 2012b). 9-Hydroxyellipticine and 7-hydroxyellipticine are primarily 
generated by CYP1A1 whereas ellipticine N2-oxide is mainly generated by CYP2D6 (Fig. 1) 
(Stiborová et al., 2004; 2011).  
There are, however, several phenomena that can limit the clinical use of ellipticine and/or 
limit its anticancer efficiency. For instance, the clinical application of ellipticine is greatly 
limited by hydrophobicity and severe adverse toxic effects, including nephrotoxicity, 
hemolysis, xerostomia, hypertension, nausea and vomiting (Garbett and Graves, 2004; 
Stiborová et al., 2011; Stiborova and Frei, 2014). To some extent, the development of 
chemoresistance has been observed (Poljaková et al., 2009; Procházka et al., 2012; Hrabeta et 
al., 2015). One approach in mitigating these adverse effects is the encapsulation of ellipticine 
inside suitable nanocarrier, allowing targeted delivery to the tumor tissue while avoiding 
healthy cells (Chomoucka et al., 2010; Petros and DeSimone, 2010; Ali et al., 2011; Ryvolova 
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et al., 2012; Svenson, 2012; 2013; Dostalova et al., 2016). These nano-sized carriers can reach 
disease tissue and tumor cells via passive targeting (due to their size) (Dostalova et al., 2016) 
and/or active targeting (due to specific moieties on their surface) (Dostalova et al., 2016; Wu et 
al., 2012). Various materials have been tested for targeted ellipticine delivery, including 
peptide-based nanoparticles (Wu et al., 2012; Wan et al., 2016), polyHPMA-ellipticinium 
conjugates (Sedlacek et al., 2013), particles based on the triblock copolymer poly(ethylene 
oxide)-block-[tert-butylacrylamide-co-6-(N-methacryloylamino)-hexanoic acid hydrazide]-
block-poly(ethylene oxide) (Studenovský et al., 2015) poly(ethylene oxide)-block-poly(allyl 
glycidyl ether) block copolymer-based micelles (P 1191 nanoparticles) (Stiborova et al., 2014a; 
2015b), and octyl glucoside micelles (Gavvala et al., 2014). These nano-formulations seem to 
offer a promising way in overcoming some of the side effects of ellipticine (Sedlacek et al., 
2013; Gavvala et al., 2014; Stiborova et al., 2014a; 2015b). Besides these nanocarriers, those 
prepared using ubiquitous proteins or protein cages also appear suitable for several anticancer 
drugs such as doxorubicin (Yang et al., 2007; Liang et al. 2014; Dostalova et al., 2016; 2017) 
and might therefore also be considered a suitable alternative for targeted ellipticine delivery. 
They are naturally biocompatible and biodegradable, and provide receptor-mediated passage 
through the cell membranes (Dostalova et al., 2016). 
Apoferritin (Apo) is a naturally occurring iron-storage protein consisting of 24 protein 
subunits responsible for the storage and transfer of iron (Gallois et al., 1997; Kim et al., 2011; 
Kilic et al., 2012; Tmejova et al., 2013; Blazkova et al., 2013; Heger et al., 2014) that provides 
much needed properties of a drug-nanocarrier. Various ferritins are internalized by transferrin 
receptor 1 (TfR1) or scavenger receptor class A member 5 (SCARA5), overexpressed on 
membranes of some tumor cells (Mendes-Jorge et al., 2014). This can enable natural active 
targeting to those tumor cells, while passive targeting to tumor tissues is facilitated by the size 
of the ferritins (Blazkova et al., 2014; Heger et al., 2014). Apo protein subunits assemble to 
form a hollow cage with internal and external size of 8 and 12 nm in diameter, respectively, 
into which diverse low-molecular substances, such as drugs, can be placed (Uchida et al., 2007). 
It was shown that while disassembled, Apo protein subunits can be mixed with drug molecules 
and they are encapsulated within Apo cavity once reassembled (Blazkova et al., 2014; Heger et 
al., 2014). Using Apo as a nanocarrier has the potential to move undetected through the body 
without inducing any immune reaction. Furthermore, this natural protein can be modified with 
recognition ligands to achieve tumor-specific targeting (Dostalova et al., 2016; 2017). These 
extra modifications can avoid renal clearance and ensure enhanced permeability and retention 
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effect. However, they might disturb the Apo in vivo performance and biocompatibility due to 
altered surface physicochemical properties of ferritin (Dostalova et al., 2016). 
The aim of this study was to construct a nanocarrier based on apoferritin-containing 
encapsulated ellipticine (ApoElli). Therefore, we developed a simple-to-use encapsulation 
protocol in this study to creating ApoElli. Further, the prepared ellipticine-bearing nanocarriers 
were characterized and their biochemical and cytotoxic properties investigated. We also studied 
the CYP-facilitated formation of ellipticine-derived DNA adducts using ApoElli. 
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2. Material and methods 
 
2.1. Chemicals and reagents  
Ellipticine, NADPH (as tetrasodium salt; ~98% purity), apoferritin (L-chain ferrritin) from 
horse spleen, dilauroyl phosphatidylcholine (DLPC), glutathione, calf thymus DNA, and others 
were purchased from Sigma-Aldrich (St. Louis, MO, USA) in ACS purity (purity meets the 
standards of American Chemical Society), unless noted otherwise. Testosterone and 6-β-
hydroxytestosterone were purchase from Merck (Darmstadt, Germany).  
 
2.2. Enzymatic systems 
Human CYP3A4 expressed in SupersomesTM (CYP3A4-SupersomesTM), microsomes isolated 
from insect cells transfected with a baculovirus construct containing cDNA of human CYP3A4, 
NADPH:cytochrome P450 oxidoreductase (POR) and cytochrome b5 (molar ratio of CYP3A4 
to cytochrome b5 of 1 to 5), were purchased from Corning (Tewksbury, MA, USA). The 
enzymatic activity of the experimental CYP3A4-SupersomesTM system used was verified by 
studying its efficiency to catalyze 6-β-testosterone hydroxylation, a marker reaction for 
CYP3A4 (see below).  
 
2.3. Preparation of apoferritin-bound ellipticine  
The stock solution of ellipticine (1 mg/ml) was prepared by dissolving ellipticine in distilled 
water with addition of 1 M HCl (at a ratio of water to HCl of 150 to 1). Ellipticine was 
encapsulated into apoferritin as follows: 200 µl of horse spleen Apo (50 mg/ml) was added to 
2 ml of distilled water and 1 ml of ellipticine (1 mg). The pH was lowered from 6.7 to 2.7 by 
HCl to disassemble the Apo structure, and the mixture was shaken for 15 min to create a 
homogeneous solution. After mixing, the pH was adjusted again to neutral pH (7.2), by adding 
7 µl of 1 M NaOH. The solution was mixed again for 15 min to enable the reassembly of the 
Apo molecule and encapsulation of ellipticine molecules within (creating ApoElli). The sample 
was diafiltrated three times with water using Amicon® Ultra - 0.5 ml 3K (Merck Millipore, 
Billerica, MA, USA) at 15,000g for 5 min. The parental molecule of ellipticine was stable under 
the conditions used for the preparation of ApoElli nanoparticles. The amount of ellipticine 
encapsulated in the Apo nanoparticles were determined using fluorescence detection (excitation 
wavelength 434 nm, emission wavelength 541 nm). The final concentration of ellipticine in 
ApoElli samples was 2.2 mM.  
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2.4. Characterization of ApoElli nanocarrier during storage 
For every period of storage, aliquots were collected and prematurely released ellipticine was 
removed by diafiltration with distilled water using the Amicon® Ultra - 0.5 ml 3K (Merck 
Millipore, Billerica, MA, USA) at 13,000g for 15 min. The stability of ApoElli nanoparticles 
(1.7 mM stock solution) was determined after their incubation in distilled water at ‒20°C and/or 
+4°C for up to 10 weeks. Aliquots (150 µl) were diluted twice with water and diafiltrated using 
Amicon® Ultra - 0.5 ml 3K (Merck Millipore, Billerica, MA, USA) at 13,000g for 5 min. 
Ellipticine was extracted from 100 µl of ApoElli twice with 1 ml of ethyl acetate, the solvent 
was evaporated to dryness and residues were dissolved in 25 µl of methanol prior to analysis. 
Released and retained ellipticine was measured using HPLC as previously described (Stiborová 
et al., 2004; 2017). 
Visualization and the average size of ApoElli nanocarriers prior to removal of released 
drug molecules and the Apo nanocarriers without ellipticine were performed using transmission 
electron microscopy (TEM) with negative staining technique. For this purpose, an 
organotungsten compound, Nano-W (Nanoprobes, Yaphank, NY, USA) was utilized. Then, 4 
μl of samples was deposited onto 400-mesh copper grids coated with a continuous carbon layer. 
Dried grids were imaged by TEM (Tecnai F20; FEI, Hillsboro, OR, USA) at 80,000× 
magnification. 
The average size of Apo and ApoElli was also determined by quasielastic dynamic light 
scattering (DLS) with a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). The 
nanocarrier was diluted to a concentration of 10 µg/ml of Apo, placed into polystyrene latex 
cells, and measured at a detector angle of 173°, wavelength of 633 nm, and temperature of 
25°C, with refractive index of dispersive phase 1.45 and 1.333 for dispersive environment. For 
each measurement, Zen0040 disposable cuvettes (Brand GmbH, Wertheim, Germany) were 
used, containing 50 μl of sample. Equilibration time was 120 seconds. Measurements were 
performed in hexaplicate. 
The surface zeta potential (ζ-potential) of the nanocarrier diluted to 20 µg/ml of Apo was 
measured using the Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). For each 
measurement, disposable cells (DTS1070) were employed. The number of runs varied between 
20 and 40, and calculations considered the diminution of particle concentration based on the 
Smoluchowski model, with an F(ka) of 1.5 and an equilibration time of 120 sec. Measurements 
were performed in triplicate. 
 
2.5. The effect of pH on release of ellipticine from ApoElli nanoparticles 
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 The released free ellipticine (from ApoElli) at different incubation times was determined by 
HPLC as previously described (Stiborová et al., 2004; 2017). To assay for the release of 
ellipticine, ApoElli sample (1.7 mM; 500 µl) were placed in a D-tube (molecular weight cut-
off 3 kDa, D-Tube Dialyzer midi; (Novagen, Darmstadt, Germany) and incubated with gentle 
stirring in 14.5 ml of 0.1 M potassium phosphate buffer pH 6.5 and/or 7.4 at 37°C in the dark. 
500 µl of buffer with released ellipticine was replaced and extracted twice with 1 ml of ethyl 
acetate at each time point. The solvent was evaporated to dryness and residues were dissolved 
in 25 µl of methanol before HPLC analysis. 
 
2.6. Incubations to study 6-β-testosterone hydroxylation by CYP3A4 in SupersomesTM 
The incubation mixtures for measuring the testosterone metabolism contained in a final volume 
of 0.25 ml: 100 mM potassium phosphate buffer (pH 7.4 or 6.5), 50 µM testosterone (1.25 μl 
of stock methanol solution per incubation), 1 mM NADPH, and 100 nM human recombinant 
CYP3A4 in SupersomesTM with cytochrome b5. The reaction was initiated by adding NADPH, 
the cofactor CYP-mediated enzyme system present in SupersomesTM. Negative control 
reactions lacked either CYP3A4-SupersomesTM systems or cofactors or testosterone. After 
incubation for 15 min at 37oC, 5 μl of 1 mM phenacetin in methanol was added as an internal 
standard; testosterone oxidation was linear up to 30 min of incubation (data not shown). The 
reaction was terminated by the addition of 0.1 ml of 1 M aqueous Na2CO3 containing 2 M NaCl. 
The metabolites were extracted twice with 1 ml of dichloromethane and extracts were 
evaporated to dryness. The residues were dissolved in the mobile phase for HPLC (see below). 
Testosterone and its metabolite 6-β-hydroxytestosterone were separated on Nucleosil (C18) 
HPLC column (4.6 × 25 mm, 5 µm, Macherey-Nagel, Germany). The flow rates, mobile phases 
and detection wavelength were 0.6 ml per min, 65:35 methanol/H2O (v/v), and 254 nm, 
respectively (Bořek-Dohalská et al., 2001; 2010). 
 
2.7. Ellipticine release from ApoElli nanoparticles, its transfer into SupersomesTM containing 
human CYP3A4 and cytochrome b5, and determination of its metabolism 
Release of ellipticine from ApoElli nanoparticles in the presence of CYP3A4-SupersomesTM 
with cytochrome b5, its transfer into these subcellular membrane particles and its ability to be 
metabolized were investigated in incubation mixtures of these particles in 0.1 M sodium 
phosphate buffer pH 6.5 and/or 7.4 for 20 min at 37°C. Incubation mixtures contained in a final 
volume of 0.25 ml: 100 mM potassium phosphate buffer (pH 6.5 or 7.4), 1 mM NADPH, 100 
nM human recombinant CYP3A4 in SupersomesTM co-expressed with POR and cytochrome 
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b5, and 25 μM free ellipticine or ApoElli. Stock solution of free ellipticine was 2.5 mM in 
dimethylsulfoxide (DMSO). Stock solution of Apo-bound form of ellipticine was 2.2 mM in 
water. The reaction was initiated by adding NADPH. Control incubations lacked either 
CYP3A4-SupersomesTM, cofactor (NADPH), ellipticine or ApoElli. After incubation for 20 
min at 37°C, 5 μl of 1 mM phenacetin in methanol was added as an internal standard. Ellipticine 
metabolites were extracted twice with 1 ml ethyl acetate, solvent was evaporated to dryness, 
residues were dissolved in 25 μl methanol and ellipticine metabolites were separated by HPLC 
as reported (Stiborová et al., 2004; 2017). 
 
2.8. Ellipticine release from ApoElli nanoparticles and its transfer into liposomes 
Liposomes are a form of vesicles mimicking the properties of microsomes that consist either of 
many, few or just one phospholipid bilayers. For the present study they were prepared as 
described previously (Stiborová et al., 2001) with minor modifications. Briefly, liposomes were 
prepared from dilauroyl phosphatidylcholine dissolved in chloroform (20 mg/ml). A lipid film 
was obtained by rotary evaporation of chloroform. Residual chloroform was removed by a 
stream of nitrogen. The lipid film was further dispersed with 0.1 M sodium phosphate buffer 
pH 7.4 and ultrasonicated twice at 20°C for 3 min each. In these vesicles amphiphilic and 
lipophilic molecules are solubilized within the phospholipid bilayer according to their affinity 
towards the phospholipids (Kulkarni et al., 2011). Because of these properties the possible 
transfer of ellipticine from ApoElli nanoparticles to these liposomes was tested. Appropriate 
amounts of ApoElli nanoparticles (2.2 mM ellipticine in ApoElli sample) were added to the 
prepared liposomes dispersed in 0.1 M sodium phosphate buffer pH 7.4 and the mixture was 
incubated for 20 min at 37°C. Liposomes were re-precipitated with 1 mM calcium chloride and 
centrifuged at 15,000g for 10 min as described (Kamath et al., 1971). Control incubations were 
carried out with the incubation mixture containing these components but in the absence of 
liposomes. The amounts of ellipticine present in the pellet of liposomes obtained by 
precipitation from the incubation mixture and in residual ApoElli nanoparticles retained in 
supernatant of these incubations were determined by HPLC (Stiborová et al., 2004; 2017). 
Likewise, the amounts of ellipticine present in pellet obtained by precipitation of the control 
incubation mixture (without liposomes) and in residual supernatant were determined by HPLC. 
Ellipticine from the samples was extracted twice with 1 ml ethyl acetate, solvent was evaporated 
to dryness, and residues were dissolved in 25 μl of methanol prior to HPLC analysis. 
 
2.9. Determination of DNA adduct formation by ellipticine and ApoElli by 32P-postlabeling 
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Incubation mixtures used to assess DNA adduct formation by ellipticine and ApoElli contained 
0.5 mg protein of 100 nM human recombinant CYP3A4 in SupersomesTM with POR and 
cytochrome b5 (500 nM), 0.1 mM ellipticine (dissolved in 7.5 μl DMSO) or ApoElli (in 
deionized water), and 0.5 mg of calf thymus DNA in a final volume of 0.75 ml as described 
previously for free ellipticine (Stiborová et al., 2004; 2012a; 2012b). The reaction was initiated 
by adding 0.1 mM ellipticine (in free or Apo-bound form) and incubations were carried out for 
60 min at 37°C. Ellipticine-derived DNA adduct formation has been shown to be linear up to 
90 min (Stiborová et al., 2004; 2012a; 2012b).   Control incubations were carried out without 
CYP3A4-SupersomesTM, or without NADPH, DNA, ellipticine or ApoElli. After incubation, 
DNA was isolated from the residual water phase by standard phenol/chloroform extraction. 
DNA adduct formation was analyzed using the nuclease P1 enrichment version of the 32P-
postlabeling assay (Stiborová et al., 2004; 2012a; 2012b). Resolution of the adducts by thin-
layer chromatography (TLC) using polyethylenimine (PEI)-cellulose plates (Macherey and 
Nagel, Düren, Germany) was carried out as described (Stiborová et al., 2004; 2011; 2012a; 
2012b). DNA adduct levels (RAL, relative adduct labeling) were calculated as described 
(Schmeiser et al., 2013). 
 
2.10. Cell culture 
The UKF-NB-4 cell line, established from bone marrow metastases of recurrent high-risk 
neuroblastoma, was a generous gift of Prof. Jindrich Cinatl, Jr. (University of Frankfurt, 
Germany). Neonatal human dermal fibroblasts (HDFn) were purchased from Thermo Fisher 
Scientific (Waltham, MA, USA). Cells were grown at 37°C and 5% CO2, cultivated in Iscove’s 
modified Dulbecco’s medium (IMDM) with 10% fetal bovine serum and HDFn in DMEM 
(Dulbecco’s Modified Eagle Medium) (all Life Technologies, Carlsbad, CA, USA). UKF-NB-
4 and HDFn cells were cultivated for at least 48 hours with free ellipticine or ApoElli 
nanoparticles; this incubation time was chosen as it essentially corresponds to two rounds of 
cell division (Poljaková et al., 2009). Moreover, this time period is sufficient for ellipticine to 
enter the cells and trigger apoptosis (Kim et al., 2003; Poljaková et al., 2009).  
 
2.11. AlamarBlue assay 
Cytotoxicity of ellipticine and ApoElli nanoparticles in neuroblastoma UKF-NB-4 and non-
malignant HDFn cells was determined in a 96-well plate format. For dose-response curves, cells 
were seeded in 100 µl of medium at a density of 1×104 UKF-NB-4 or 5×103 HDFn cells per 
well. Cells were treated with ellipticine or ApoElli nanoparticles (concentration of 0.04-20 µM) 
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and incubated for 48 hours. Cell viability was evaluated by the AlamarBlue assay as previously 
described (Plch et al., 2018). Briefly, after 48 hours incubation at 37°C in 5% CO2, 5 µl of 
AlamarBlue (Thermo Fisher Scientific, Waltham, MA, USA) was added to each well and the 
plates were incubated for 2 hours. The fluorescence was measured using excitation wavelength 
of 570 nm and emission of 610 nm by SpectraMax® i3x Multi-Mode Microplate Reader 
(Molecular Devices, Sunnyvale, CA, USA). The (48 hours)-IC50 values were calculated from 
at least 3 independent experiments by SOFTmaxPro software. 
 
2.12. Annexin V/DAPI double staining assay 
For detection of apoptosis, Annexin V-Dy647 (Apronex s.r.o, Jesenice u Prahy, Czech 
Republic) staining was used according to the manufacturer’s instructions and samples were 
analysed using flow cytometry (LSR II, BD, Franklin Lakes, CA, USA). Briefly, 8×105 UKF-
NB-4 cells and 4×105 HDFn cells were plated in 60 mm dishes and treated with 5 µM ellipticine 
or ApoElli nanoparticles. After 48 hours incubation, cells were washed with PBS, trypsinized, 
collected by centrifugation and resuspended in 100 μl of Annexin binding buffer containing 1 
μl of Annexin V-Dy647 and 10 μg/ml of 4’,6-diamidino-2-phenylindole, dihydrochloride 
(DAPI, Thermo Fisher Scientific, Waltham, Massachusetts, USA), cells were gently vortexed 
and incubated for 15 min at room temperature in the dark. After incubation, cells were washed 
again in PBS and resuspended in 300 μl of binding buffer and measured using flow cytometer 
and subsequently analysed by FlowLogic software (Inivai Technologies, Mentone, Australia). 
 
2.13. Cell cycle analysis 
In order to evaluate cell cycle distribution, 8×105 UKF-NB-4 and 4×105 HDFn cells were plated 
in 60 mm dishes and exposed to 5 µM individual ellipticine forms and 5 µM ApoElli 
nanoparticles in deionized water. After 24 hours exposure, cells were collected by 
trypsinization, washed by PBS and fixed with 4% paraformaldehyde for 10 min. Thereafter 
these cells were permeabilised with 90% ice cold methanol and incubated at ‒20°C for a 
minimum of 1 hour. Samples were additionally incubated in DAPI (10 µg/ml) solution in dark 
under the laboratory temperature for 30 min, washed with PBS, and measured by flow 
cytometry employing LSR II flow cytometer and percentage of cells in G0/G1, S and G2/M 
was analysed with FlowLogic software (Inivai Technologies, Mentone,  Australia). 
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2.14. Real-time monitoring of cell viability The xCELLigence RTCA DP Instrument (ACEA 
Bioscience Inc., San Diego, CA, USA) placed in a humidified incubator at 37°C and 5% CO2 
was used for real-time label free monitoring of cell viability (Ke et al., 2011). UKF-NB-4 cells 
(15,000 cells) were seeded into wells of 16-well plates for impedance-based detection. Cells 
were treated with 2.5 µM ellipticine or the same concentrations of ellipticine in ApoElli 
nanoparticles. The cell index (CI) was monitored every 30 min for 148 hours and data was 
recorded by the supplied RTCA software. 
 
2.15. Histone H2AX phosphorylation status 
To determine phosphorylation of histone H2AX, 8×105 UKF-NB-4 and 4×105 HDFn cells were 
plated in 60 mm dishes and treated with 5 µM ellipticine or ApoElli nanoparticles for 48 hours. 
After treatment, cells were washed and subsequently fixed in 4% formaldehyde in PBS for 10 
min. After washing with PBS, cells were re-suspended in ice cold 90% methanol and incubated 
for 1 hour at ‒20°C. Cells were washed three times with wash buffer (PBS containing 0.5% 
BSA and 0.2% Triton X) and then incubated in 50 μl of wash buffer containing 5 μl of γH2AX 
antibody (Alexa Fluor® 647 anti-H2AX-Phosphorylated (Ser139), Biolegend, San Diego, CA, 
USA) for 60 min at 4°C. Cells were washed, measured using a LSR II flow cytometer (BD, 
Franklin Lakes, CA, USA) and analysed with FlowLogic software. 
 
2.16. Confocal microscopy 
5×105 UKF-NB-4 or 2.5×105 HDFn cells were grown on 35 mm glass bottom culture dishes (In 
Vitro Scientific, Sunnyvale, CA, USA) for 24 hours before treatment with 10 μM ellipticine or 
10 μM ApoElli for 2 hours at 37°C and observed with a laser-scanning confocal microscope, 
Leica TCS SP8 (Leica Microsystems GmbH, Wetzlar, Germany). For excitation of the 
ellipticine, laser with wavelength of 488 nM was used; emitted light was collected in the range 
of 552–638 nM. All images were recorded with a ×100 objective and using the Leica 
Application Suite X (LAS X) system. Nuclear fluorescence intensity of ellipticine was 
evaluated with the image analysis software ImageJ (NIH, Bethesda, USA) and calculated as the 
corrected total cell fluorescence (CTCF), using the formula CTCF = Integrated Density – (Area 
of selected nuclei × Mean fluorescence of background readings). 
 
2.17. Analysis of cellular ellipticine 
 The day before analysis, UKF-NB-4 cells were seeded at 1×104 UKF-NB-4 and HDFn at 5×103 
cells per well in 96-well plate. Cells were treated with 10 μM ellipticine or 10 μM ApoElli for 
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2 hours at 37°C and fluorescence intensity of ellipticine was measured (excitation wavelength 
434 nm, emission wavelength 541 nm) with a SpectraMax® i3x Multi-Mode Microplate Reader 
(Molecular Devices, Sunnyvale, CA, USA) in individual cells using imaging cytometer module. 
 
2.18. Red blood haemolytic test  
The haemolytic assay was conducted to evaluate the haemocompatibility of Apo and ApoElli 
on erythrocytes from human donor with signed informed consent. Plasma from a fresh blood 
sample was removed by multiple washing with 150 mM sodium chloride and centrifugation at 
3000 rpm for 10 min. Then different concentrations of Apo and ApoElli (6.3-100 µM ellipticine 
in ApoElli and 13.8-220 µg/l Apo) in PBS pH 7.4 were mixed with the red blood cells (RBC) 
and incubated for 1 hour at 37°C. PBS and 0.1% Triton X-100 was used as negative and positive 
control, respectively. After completion of the incubation period, the cells were centrifuged and 
the absorbance of the supernatant containing lysed erythrocytes was measured at 540 nm. The 
percentage of haemolysis was determined by the following equation: 
                                                                          (At - Ac) 
                                        % Haemolysis =  ---------------------  × 100 
                                                                        (A100% - Ac) 
 
where At is the absorbance of the supernatant from samples incubated with the particles; Ac is 
the absorbance of the supernatant from negative control (PBS) and A100% is the absorbance of 
the positive control supernatant (completely lysed RBC incubated in the presence of 0.1% 
Triton X-100) (Goswami et al., 2015). 
 
2.19. Western blot analysis of SCARA5 
1×106 cells of each cell line (UKF-NB-4 and HDFn cells) was harvested by trypsinization, then 
centrifuged at 200 rcf for 10 min and washed with PBS with subsequent centrifugation at 200 
rcf for further 10 min. The pellet was resuspended in 100 µl of ice-cold RIPA lysis buffer (20 
mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium 
deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM glycerophosphate, 1 mM Na3VO4, 1 
μg/ml leupeptin) containing 1 µl of protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, 
USA) and vortexed for 15-30 sec. Lysis was then performed on ice for 45 min. Lysate was 
sonicated 5 times for 3 sec to remove genomic DNA. After centrifugation for 10 min at 22 000 
rcf, the supernatant containing proteins was stored at −80°C until analysis. 10 µl containing 10 
µg of proteins was mixed with 5 µl of non-reducing SDS-PAGE loading buffer prior to 
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separation on 12.5% SDS-PAGE at 200 V for 35 min. Proteins were electroblotted onto a PVDF 
membrane. The PVDF membrane was blocked with 5% bovine serum albumin in PBS (37 mM 
NaCl, 2.7 mM KCl, 1.4 mM NaH2PO4, 4.3 mM Na2HPO4, pH 7.4) and then incubated 
separately with primary antibodies against SCARA5 (1 µg/ml = 1:1000, ab118894, Abcam), or 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) G-9 (1:700, sc-365062, Santa Cruz 
Biotechnology) at 4°C overnight. Next, the membranes were incubated with horseradish 
peroxidase (HRP)-labelled secondary antibodies (goat anti-mouse P0260 [Dako] for GAPDH, 
1:5000 or goat anti-rabbit SAB3700831 [Sigma Aldrich] for SCARA5, 1:5000) for 1 hour at 
25°C. Chemiluminiscent detection was performed using Clarity Western ECL Blotting 
Substrate (Bio-Rad, CA, USA) and bands were analysed using Azure c600 imager (Azure 
Biosystems, Dublin, CA, USA). The membranes were visualized and processed using Azure 
c600 (Azure Biosystems, Dublin, CA, USA). 
 
2.20. Detection of ellipticine-DNA adducts in UKF-NB-4 cells by 32P-postlabeling 
 Neuroblastoma UKF-NB-4 cells were seeded 24 hours prior to treatment at a density of 1×105 
cells/ml in three 75 ml culture flasks in a total volume of 20 ml of IMDM. Cells were treated 
with 5 μM ellipticine or 5 μM ApoElli nanoparticles for 48 hours. Cells were harvested after 
trypsinizing by centrifugation at 2,000×g and washed twice with 5 ml of PBS yielding a cell 
pellet which was stored at ‒80ºC until DNA isolation. DNA was isolated using a standard 
phenol-chloroform extraction method as described (Frei et al., 2002; Poljaková et al., 2007; 
2009; Stiborova et al., 2015a). Ellipticine-DNA adducts were detected and quantified using the 
nuclease P1 enrichment version of the 32P-postlabeling assay as described previously for in 
vitro (Frei et al., 2002; Poljaková et al., 2007; 2009; Stiborova et al., 2015a) and in vivo analyses 
(Stiborová et al., 2003a; 2003b; 2008; 2011; 2014a). 
 
2.21. Statistical analysis 
Data are expressed as mean ± SD. Data was analysed using GraphPad Prism 7 using ANOVA 
with post-hoc Tukey HSD Test. P value < 0.05 was considered as significant.  
 
 
3. Results and discussion 
 
3.1. Preparation of apoferritin-bound ellipticine (ApoElli) nanoparticles 
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Apoferritin (Apo) is known to reversibly dissociate and associate, which are processes 
dependent on pH (Kim et al., 2011). When Apo is disassembled after mixing it with drug 
molecules, these molecules can encapsulate within the Apo cavity once reassembled (Kilic et 
al., 2012; Blazkova et al., 2013; Tmejova et al., 2013). As shown in Fig. 2 we utilized this easy-
to-use encapsulation protocol to prepare Apo nanoparticles encapsulated with the anticancer 
agent ellipticine (ApoElli). The ellipticine concentration in the prepared ApoElli nanoparticles 
was 2.2 mM. 
Size is one of the most important parameters influencing the in vivo biodistribution of 
nanocarriers and has a great impact on the mode of cellular internalization (Petros and 
DeSimone, 2010). Nanocarriers with the size of 20-100 nm are considered best suitable for 
enhanced permeability and retention (EPR) effect (Svenson, 2016), while avoiding 
extravasation from normal blood vessels which occurs only with particles below 10 nm 
(Appelbe et al., 2016). This also avoids removal from the body through renal clearance for 
particles below 5 nm or elimination by the reticuloendothelial system (RES) which traps 
particles above 100 nm (Liu et al., 2016).  Visualization of the ApoElli nanocarriers and 
determination of their size prior to removal of released drug molecules and the Apo nanocarriers 
without ellipticine were performed using TEM (Fig. 3A) and DLS (Fig. 3B). The average size 
of Apo and ApoElli nanoparticles determined by DLS were 11.7 ± 0.31 (n=6)  and 10.1 ± 0.57 
nm (n=6), respectively (Fig. 3B,C). Even though the reasons for these small differences 
between Apo and ApoElli nanoparticles still needs to be explained, one can speculate that they 
can result from the process of encapsulation. Specifically, some Apo subunits seem not to be 
properly reassembled and thus remain in solution. Their size might thereafter decrease the 
analysed value of the average size of ApoElli. However, this suggestion remains to be 
confirmed in future investigations. The lower size of ApoElli particles than those of Apo is not 
seen using TEM without a high resolution module (Fig. 3).  
We also utilized the DLS method to determine the polydispersive index and the surface 
ζ-potential of the prepared nanoparticles. The polydispersive index is used as a measure of the 
breadth of molecular weight distribution of polymers. For Apo and ApoElli nanoparticles this 
was 0.350 ± 0.09 (n=6) and 0.419 ± 0.24 (n=6), respectively (Fig. 3C), indicating very well 
homodispersed systems (Gaumet et al., 2008). The surface ζ-potential of Apo and ApoElli 
nanocarriers showing the electrostatic potential at the electrical double layer surrounding both 
nanoparticles in solution was also characterized. The average values of -32.0 ± 2.02 (n=6)  and 
-36.2 ± 2.65 (n=6) for Apo and ApoElli, respectively (Fig. 3C), indicate that they are strongly 
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anionic (Clogston and Patri, 2011). High values of ζ-potential result in strong repulse moments 
among the particles leading to the stability of these colloidal disperse systems.  
Next we evaluated the stability of ApoElli (i.e. the degree of ellipticine release) at two 
different temperatures (‒20°C and +4°C) for up to 10 weeks. As shown in Figure 4A, ApoElli 
was stable for up to 10 weeks of storage at +4°C. Essentially no ellipticine was released under 
these storage conditions whereas ellipticine was markedly released during storage at ‒20°C; 
25% and 60% of ellipticine is released from ApoElli in 2 and 10 weeks, respectively.  
One of the reasons that Apo was chosen in our experiments was its ubiquitous presence 
in nature and its natural property to self-assemble into                         
uniform icosahedral nanocages that are highly stable and do not form aggregates in the 
physiological environment (Gallois et al., 1997). Using TEM, we essentially found no changes 
in aggregation of ApoElli nanocarriers as well in their shape and size after storage for 28 days 
at +4°C (compare Figs. 3Ab and 3Ac).  
All these findings demonstrate that the prepared ApoElli nanoparticles with the average 
size of 10.1 ± 0.57 (n=6) nm form a homogenous system with a low polydispersity and high 
colloidal stability. This suggests their high suitability for nanomedicine; for example because 
of their stability during the storage and the size appropriate for EPR internalization (Moore et 
al., 2015) 
 
3.2. Release of ellipticine from ApoElli nanoparticles 
To investigate the release of ellipticine from ApoElli nanoparticles they were incubated either 
at pH 6.5 or pH 7.4 for 48 hours at 37°C and the release of ellipticine was subsequently 
monitored using HPLC. The release of ellipticine from the ApoElli nanoparticles proceeded in 
two stages: an initial rapid release was followed by a phase of slow and long-lasting release of 
ellipticine (Fig. 4B). At pH 7.4 ApoElli nanoparticles were essentially stable; less than 20% 
release of free drug was found over 48 hours of incubation. In contrast, at pH 6.5 ellipticine 
release was detected with a half-life of 7 hours and the maximum release of 83 ± 7% was 
reached after 48 hours (Fig. 4B). The pH-dependent release of ellipticine might be caused by 
at least two reasons. First, at pH 6.5 changes in the ApoElli structure might occur resulting in 
disintegration of Apo to its subunits (see scheme in Fig. 2) (Kim et al., 2011). This is a typical 
feature for pH-related changes to the peptide/apoferritin nanoparticle structure (Kim et al., 
2011; Zhang et al., 2019).  Second, the ellipticine as a hydrophobic base compound is easily 
released from the ApoElli nanoparticles into the water environment under the acidic conditions. 
These acidic conditions are typical for tumor microenvironments (Corbet and Feron, 2017).  
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3.3. Ellipticine release from ApoElli in the presence of CYP3A-SupersomesTM, its transfer 
into these subcellular particles and its oxidation by this enzymatic system 
Incubations of both free ellipticine and ApoElli with SupersomesTM containing human 
CYP3A4, POR and cytochrome b5 were employed to analyze the transfer of ellipticine from 
both forms of this drug into these subcellular membrane particles. For this purpose we studied 
the CYP3A4-facilitated metabolism of free and ApoElli bound ellipticine. In order to evaluate 
the suitability of CYP3A4-SupersomesTM for our experiments, we tested the system to catalyze 
testosterone 6-β-hydroxylation as a marker for CYP3A4 enzyme activity (Bořek-Dohalská et 
al., 2001). As shown in Figure 5A our results demonstrated that the Supersomal CYP3A4 
system can catalyze this marker reaction and thus we can argue that CYP3A4-SupersomesTM 
are a suitable system for our enzymatic studies. 
CYP3A4-SupersomesTM incubated with free ellipticine in the presence of NADPH were 
capable of oxidizing ellipticine to 9-hydroxy-, 12-hydroxy- and 13-hydroxyellipticine (Fig. 
5B); NADPH acts as cofactor for the CYP-mediated enzyme system present in SupersomesTM. 
The same metabolites were also generated in the presence of ApoElli nanoparticles in the 
incubation mixtures instead of free ellipticine. Beside these ellipticine oxidation products, two 
other metabolites, 7-hydroxyellipticine and ellipticine N2-oxide were also detectable. However, 
their amounts were quite low (if detectable) and therefore were not quantified. The oxidation 
of free ellipticine and ApoElli was pH-dependent. By lowering pH from 7.4 to 6.5 oxidation of 
ellipticine was decreased; the amounts of ellipticine metabolites were up to 5-times lower at pH 
6.5 than pH 7.4 (Fig. 5B). The effect of the pH on CYP3A4-mediated catalysis was confirmed 
by measuring testosterone 6-ß-hydroxylation. Our results indicated that this reaction was also 
decreased at low pH, but this effect was less pronounced compared to ellipticine oxidation 
(compare Figs. 5A and 5B).  
Interestingly, at pH 7.4 the amounts of ellipticine metabolites generated by CYP3A4 in 
the presence of NADPH were similar regardless of either form of ellipticine (free ellipticine 
and ApoElli) (Fig. 5B). Although ApoElli nanoparticles are stable at this pH (see Fig. 4B), the 
generation of ellipticine metabolites indicated that this drug is efficiently released from the 
apoferritin cage in ApoElli nanoparticles not only at pH 6.5, but even at pH 7.4. The amounts 
of ellipticine metabolites formed from ApoElli were only up to 1.4-fold lower compared to 
those formed from free ellipticine at both pH levels. This finding indicates that the presence of 
the microsomal membrane of SupersomesTM is much more important for ellipticine release from 
ApoElli in this enzyme system than pH. The properties dictated by the phospholipid bilayer 
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forming the microsomal membrane of CYP3A4-SupersomesTM might be responsible for this 
unique phenomenon that has not been described yet. Interaction of ApoElli nanoparticles with 
SupersomesTM might result in the release of ellipticine from these nanoparticles entering the 
supersomal membrane system. In order to investigate this possibility we prepared liposomes 
mimicking the properties of microsomal membrane particles and incubated them with ApoElli 
nanoparticles in order to evaluate the amounts of ellipticine released from ApoElli transported 
to these liposomes. As shown in Figure 6 ellipticine was released from ApoElli nanoparticles 
and entered the liposomes, supporting the above mentioned hypothesis.  
All these results indicated that both free ellipticine and ellipticine released from ApoElli 
nanoparticles are capable of entering the system containing the membrane of endoplasmic 
reticulum, where it can be metabolized by the CYP3A4-mediated enzymatic system.  
 
3.4. Formation of ellipticine-derived-DNA adducts from free ellipticine and ApoElli 
nanoparticles by CYP3A-SupersomesTM 
In further experiments using CYP3A4-SupersomesTM in the presence of DNA we analyzed the 
formation of ellipticine-derived DNA adducts of free ellipticine and ApoElli. These 
experiments were carried out to prove the release of ellipticine from ApoElli, its transfer to 
CYP3A4-SupersomesTM and its oxidation by this enzymatic system using a further independent 
approach. As shown in Figure 1 the oxidative activation of ellipticine to the DNA reactive 
metabolites 13-hydroxy- and 12-hydroxyellipticine is catalyzed by several human CYP 
enzymes including CYP3A4 (Stiborová et al., 2012b). Ellipticine-derived DNA adduct 
formation was detected and quantified using the 32P-postlabeling method (Fig. 5C). One major 
DNA adduct was detected (see insert of Figure 5C) and was generated at both pH 6.5 and 7.4. 
This adduct spot was shown previously to be formed from ellipticine-13-ylium generated by 
decomposition of 13-hydroxyellipticine (Fig. 1) (Stiborová et al., 2004). These results 
confirmed again that ellipticine can be released from ApoElli particles at pH 7.4, when 
Supersomal microsomes were present in the test system. Adduct 2 generated from 12-
hydroxyellipticine (Fig. 1) was not detectable under the experimental conditions (i.e. CYP3A4-
SupersomesTM) used (Fig. 5C). No adducts were detected in control incubations, where Apo 
nanoparticles without encapsulated ellipticine were present or in the absence of free ellipticine 
(Fig. 5C). 
In CYP3A4-SupersomesTM apoferritin-bound ellipticine generated up to 2.5-fold lower 
levels of DNA adducts than free ellipticine (Fig. 5C). The lower DNA adducts levels formed 
from ApoElli nanoparticles could not be explained by the amounts of ellipticine metabolites 
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formed from ApoElli as these were only up to 1.4-fold lower as compared to those formed from 
free ellipticine (compare Figs. 5B and 5C). This is probably caused by the presence of Apo 
protein retaining in the incubation mixture after ellipticine release from the ApoElli 
nanoparticles and thus this protein can compete with DNA to react with reactive ellipticine 
intermediates (i.e. ellipticine-13-ylium) forming ellipticine-derived protein (Apo) adducts 
instead of DNA adducts. Indeed, the formation of ellipticine-derived protein adducts has been 
shown previously demonstrating that activated ellipticine can efficiently bind to several 
proteins (Martínek et al., 2010).  
 
3.5. Analysis of internalization of free ellipticine and ApoElli nanoparticles into UKF-NB-4 
and HDFn cells 
One of the most important properties of nanocarriers is their ability to internalize into target 
cells and the ability of its cargo to reach the cell organelle(s) where it can effectively inhibit the 
cell growth (Stylianopoulos and Jain, 2015). Therefore, we tested the internalization of ApoElli 
into the cancer cells and as a model we used the neuroblastoma UKF-NB-4 cell line, which was 
previously found to be sensitive to ellipticine treatment (Poljakova et al., 2009; 2011; Hrabeta 
et al., 2015). Neuroblastoma UKF-NB-4 cells were also chosen as a model because they not 
only overexpress TfR1 (Krausova, 2017), a cell membrane-associated glycoprotein responsible 
for incorporation of H-chain ferritin through an endocytic process (Uchida et al., 2007; 
Nakamura et al., 2012), but also SCARA5 for L-chain ferrritin (Uchida et al., 2007). Indeed, as 
shown in Figure 7A, SCARA5 was highly expressed in UKF-NB-4 cells, in contrast to normal 
human fibroblast HDFn cells which were used as a model for non-malignant cells. Both cell 
lines were treated with ellipticine, either free or encapsulated in ApoElli, and their effects on 
these cells were investigated.  
Subcellular localization of ellipticine after treatment was analyzed by confocal 
microscopy demonstrating that both forms of ellipticine enter UKF-NB-4 and HDFn cells (Fig. 
7B). As an indicator of ellipticine concentrations we measured the fluorescence intensity of 
ellipticine in whole cells (total) which was higher in HDFn cells than in UKF-NB-4 cells; in 
both cell lines the cellular ellipticine concentration was lower after ApoElli compared to free 
ellipticine treatment (Fig. 7C). No ellipticine fluorescence was detectable in the membranes of 
the tested cells (Fig. 7B). This indicates that both forms of ellipticine (free ellipticine and 
ApoElli) overcome the plasmatic membranes of these cells. The higher uptake of free ellipticine 
than ApoElli can be explained by the high hydrophobicity and the small size of this drug, which 
both dictates the easy transfer of free ellipticine across cell membranes, as compared to the 
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transport of the more polar and high-molecular ApoElli compound. As described previously 
(Zhang et al., 2016), the passive diffusion pathway is responsible for the transport of free 
ellipticine into the cells. In contrast, the size and anionic properties of ApoElli nanoparticles 
(Fig. 3) prevent such a type of transport. Therefore, endocytosis, a typical process of transport 
of particles into cells (Uchida et al., 2007; Nakamura et al., 2012), seems to play a predominant 
role in the transport of ApoElli across the cell membrane in the tested cells. Nevertheless, 
further investigations are needed to confirm this suggestion but were beyond the scope of the 
present work.  
Neuroblastoma UKF-NB-4 cells treated with either free ellipticine or ApoElli 
nanoparticles showed that ellipticine fluorescence was mainly located in cell nuclei in contrast 
to non-malignant HDFn cells; ellipticine fluorescence was more than 2-fold higher in the nuclei 
of UKF-NB-4 cells than in HDFn cells (Figs. 7B and 7D). In non-malignant HDFn cells most 
of ellipticine was located in the lysosomes after the uptake of free ellipticine and ApoElli (Figs. 
7B and 7D). These results demonstrate that both forms of ellipticine are taken up by the cell 
models but accumulate it in different compartments depending on the cell type. The lower 
fluorescence intensity of ellipticine in the cells exposed to ApoElli compared to cells exposed 
to free ellipticine might be caused not only by an easier entry of ellipticine into the cells than 
ApoElli as mentioned above, but might also be caused by a slower release of ellipticine from 
ApoElli. The amounts of ellipticine are partially retained in ApoElli nanoparticles. This 
suggestion is supported by the results from experiments investigating the release of ellipticine 
form ApoElli in the presence of liposomes or CYP3A4-SupersomesTM (see Figs. 5 and 6).  
 
3.6. Cytotoxicity and induction of apoptosis by ellipticine and ApoElli nanoparticles in UKF-
NB-4 and HDFn cells, and their effects on cell cycle distribution 
We measured the cytotoxicity of free ellipticine and ApoElli in UKF-NB-4 and HDFn cells 
using the AlamarBlue viability assay and/or real-time label-free monitoring of cell impedance. 
Apo nanoparticles where ellipticine was not present were not toxic in both cell lines (data not 
shown).  
Using the AlamarBlue viability assay the IC50 values of ellipticine in UKF-NB-4 and 
HDFn cells treated with free ellipticine were 1.1±0.05 and 2.6±0.2 μM, respectively, whereas 
for ApoElli nanoparticles the IC50 values were 1.4±0.1 and 2.9±0.3 μM, respectively (Figs. 8A 
and 8B). These findings indicate that non-malignant HDFn cells are less sensitive to ellipticine 
treatment than neuroblastoma UKF-NB-4 cells. This might be explained by ellipticine 
compartmentalization in both cell types; higher levels of ellipticine were located in nuclei of 
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UKF-NB-4 cells, the target compartment for its cell toxicity (Stiborova and Frei, 2014), while 
in HDFn cells it is efficiently internalized into lysosomes, thereby decreasing its cell toxicity 
(Hrabeta et al., 2015).  
As shown in Figure 8C, apoptosis was induced in UKF-NB-4 cells after treatment with 
5 μM ellipticine and ApoElli form. However, the potency to induce apoptosis was lower after 
exposure to ApoElli nanoparticles than free ellipticine. These results are consistent with lower 
amounts of ellipticine (determined by its fluorescence) in the nuclei of these neuroblastoma 
cells after treatment with ApoElli than with free ellipticine (see Fig. 7D). In contrast, no 
apoptosis was observed in treated HDFn cells (Fig. 8D). 
To evaluate the toxicity of the ApoElli nanocarrier to other non-malignant cells we 
performed a haemocompatibility assay in human RBC. For this purpose we used fresh blood 
from a human donor with absorbance measurement and visualization in ambient light of lysed 
RBC (Fig. 8G). The ApoElli formulation showed excellent haemocompatibility. Likewise, 
control Apo (i.e. without encapsulated ellipticine) exhibited excellent haemocompatibility (data 
not shown). 
In further experiments we studied the cell cycle distribution of UKF-NB-4 and HDFn 
cells after exposure to ellipticine and ApoElli nanoparticles. Compared to controls (i.e. 
untreated cells) exposure to both forms of ellipticine resulted in increased S and/or G2/M phase 
arrest in UKF-NB-4 cells; this effect was not seen in HDFn cells (Figs. 8E and 8F). In contrast, 
HDFn cells arrested in G0/G1 phase after ellipticine and ApoElli treatment (Fig. 8F) which 
resulted in essentially no cell growth. This feature was the reason that the cytotoxic potency of 
ellipticine and ApoElli in HDFn cells could not be analyzed using the xCELLigence system. 
But this method was used to test the cytotoxicity of ellipticine and ApoElli in UKF-NB-4 cells 
(Fig. 9). UKF-NB-4 cells cultured in the presence of 2.5 μM ellipticine and the same 
concentration of this drug present in ApoElli grow exponentially up to 116 hours in culture. 
Treatment of UKF-NB-4 cells with 2.5 μM ApoElli nanoparticles for 48 hours resulted in a 1.3-
fold decrease in the value of cell index as compared to treatment with free ellipticine (Fig. 9). 
 
3.7. The effect of treatment of UKF-NB-4 and HDFn cells with ellipticine and ApoElli 
nanoparticles on phosphorylation of H2AX histone protein 
One of the DNA-damaging mechanisms leading to ellipticine cytotoxicity is based on the 
inhibition of topoisomerase II generating double-strand DNA breaks (Zwelling et al., 1982). 
Therefore, we examined the ability of ellipticine and ApoElli nanoparticles to induce double-
strand DNA breaks in UKF-NB-4 and HDFn cells. Phosphorylation of histone H2A on serine 
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139, termed γH2AX, by kinases sensing double-strand DNA breaks is a sensitive marker of this 
type of DNA damage (Nakamura et al., 2010; Sharma et al., 2012). UKF-NB-4 and HDFn cells 
were treated with 5 μM ellipticine or ApoElli and the levels of γH2AX were examined by flow 
cytometry. Whereas essentially no phosphorylation of H2AX was observed after treatment in 
HDFn with either ellipticine or ApoElli, increased γH2AX levels were detectable in UKF-NB-
4 cells (Fig. 10A). This finding confirmed that free ellipticine or ApoElli is transported into 
cancer cells where it can reach DNA in the nucleus to cause double-strand DNA breaks. The 
lower compartmentalization of ellipticine in the nuclei of non-malignant HDFn cells explains 
the lack of this DNA damage in these cells.  
The percentage of cells with γH2AX did not correlate with the cytotoxicity of ellipticine 
and ApoElli as measured by AlamarBlue assay or Annexin V positive/DAPI positive cells 
(compare Figs. 8 and 10). The levels of DNA double-strand breaks in UKF-NB-4 cells were 
~1.3-times higher after their treatment with ApoElli compared to free ellipticine. Hence, 
ellipticine-induced cytotoxicity and apoptosis in neuroblastoma UKF-NB-4 cells after exposure 
to ApoElli seems to be linked not only to the induction of DNA double-strand-breaks, but also 
to other types of DNA damage. In order to shed more light on this phenomenon, additional 
experiments were conducted to investigate covalent ellipticine-derived DNA adduct formation 
in UKF-NB-4 cells, in which ellipticine accumulates in the nuclei. 
 
3.8. The effect of treatment of UKF-NB-4 cells with ellipticine and ApoElli nanoparticles on 
the formation of covalent ellipticine-derived DNA adducts 
Ellipticine-mediated cytotoxicity is predominantly linked to covalent DNA adducts formed 
during enzymatic CYP- and peroxidase-catalyzed activation of ellipticine (Stiborová et al., 
2011; Stiborová and Frei, 2014). Therefore, we investigated the generation of ellipticine-DNA 
adducts in UKF-NB-4 cells (sensitive to ellipticine) exposed to ellipticine and ApoElli 
nanoparticles. As done in experiment with CYP3A4-SupersomesTM (see Figure 5C) we again 
employed the 32P-postlabeling assay. As shown in Figure 10B two major DNA adducts were 
observed in UKF-NB-4 cells after exposure to free ellipticine or ApoElli nanoparticles. Adducts 
1 and 2 are generated from the ellipticine metabolites 13-hydroxyellipticine and 12-
hydroxyellipticine, respectively (Stiborová et al., 2004; 2007a).  
The levels of covalent ellipticine-derived DNA adducts in UKF-NB-4 cells correlated 
with the amounts of ellipticine in the nuclei of these cells; the levels of ellipticine-DNA adducts 
generated by ApoElli were up to ~70% of those formed by free ellipticine (see Figure 10B). 
Adduct levels not only correlated with the cytotoxicity of ellipticine and ApoElli in UKF-NB-
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4 cells as measured by AlamarBlue viability assay (Figs. 8A and 8B) but also with the degree 
of apoptosis induced by ellipticine and ApoElli in these cells (Figs. 8C and 8D). These results 
demonstrate that the formation of covalent ellipticine-derived DNA adducts seems to be 
predominantly responsible for the toxic effects of ellipticine in UKF-NB-4 cells and this 
conclusion is in accordance with other studies (Stiborová and Frei, 2014, Stiborová et al., 
2014b). 
Again, these results also demonstrate that ellipticine and ApoElli might, when 
transported into the target cells, enter these cells to cause DNA damage in the nucleus. The 
mechanism of the uptake of free ellipticine and the ApoElli nanoparticles across the membrane 
is probable by diffusion and endocytosis, respectively. However additional experiments will be 
necessary in the future to better understand this process.  
 
4. Conclusions 
Apoferritin can be used to effectively delivery the anticancer agent ellipticine into cancer cells. 
We showed that ellipticine can be encapsulated by apoferritin and subsequently be released 
from its ApoElli form. Furthermore, a unique finding of our study is that ApoElli is capable of 
transferring ellipticine into microsomal subcellular particles, where it is oxidized by the CYP-
mediated system to generate reactive hydroxylated metabolites able to form covalent DNA 
adducts. These adducts are also generated in neuroblastoma UKF-NB-4 cells exposed to both 
free ellipticine and ApoElli nanoparticles. We showed that the cytotoxicity of ApoElli is lower 
than that of the free form of ellipticine. However, more importantly, whereas ApoElli 
nanoparticles were toxic in neuroblastoma UKF-NB-4 cells, their toxicity in non-malignant 
fibroblastic HDFn cells were significantly lower. This implies the suitability of ApoElli to 
inhibit the growth and development of tested cancer cells. Compartmentalization of ellipticine 
in the nuclei of neuroblastoma UKF-NB-4 cells after treatment with both forms of ellipticine 
was responsible for the induced DNA damage (i.e. DNA-double-strand-breaks and formation 
of covalent ellipticine-derived DNA adducts) in these cancer cells. Covalent modification of 
DNA seems to be the critical factor dictating the observed cytotoxicity. In contrast to drug 
internalization into the nuclei of UKF-NB-4 cells, high amounts of ellipticine are sequestrated 
in lysosomes in fibroblastic HDFn cells. The latter effect is responsible for the lower 
concentration of ellipticine in the nuclei resulting in lower cytotoxicity and/or no apoptosis in 
these non-malignant cells.  
In conclusion, we propose that apoferritin with encapsulated ellipticine might be a suitable 
carrier to target several cancer cells including neuroblastoma. The receptors TfR1/SCARA5 
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which are commonly over-expressed in these cancer cells might help to achieve this targeting 
without the need to introduce additional moieties on the surface. Therefore, this nanoparticle 
form of ellipticine seems to be a promising tool for cancer treatment.  
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Legend to Figures 
Fig. 1. Scheme of ellipticine metabolism by CYPs (in the presence [+] or absence [-] of 
cytochrome b5 [b5]) and peroxidases showing the identified metabolites and those proposed to 
form DNA adducts. The compounds shown in brackets were not detected under the 
experimental conditions and/or not structurally characterized.  
 
Fig. 2. Scheme of preparation of ApoElli nanoparticles. 
 
Fig. 3. (A) TEM micrographs of apoferritin (a), the freshly prepared ApoElli nanocarrier (b) 
and the ApoElli nanocarrier stored for 28 days at 4°C (c). (B,C) Size, polydispersive index and 
zeta potentials of Apo and ApoElli nanocarriers. Values in (C) are mean ± SD from six 
independent experiments. 
 
Fig. 4. The ApoElli stability at +4°C (red) and –20°C (blue) in panel A. Values are mean ± SD 
from three independent experiments. **p < 0.01 significant differences of stability of ApoElli 
nanoparticles without incubations (t = 0 day) (ANOVA with post-hoc Tukey HSD Test). (B) 
The kinetics of ellipticine release from ApoElli at pH 6.5 and 7.4 at 37°C. Values are mean ± 
SD from three independent experiments.   
 
Fig. 5. (A) The effect of pH on testosterone 6-β-hydroxylation catalysed by human CYP3A4 
co-expressed with cytochrome b5 in SupersomesTM. Values are mean ± SD (pmol 6-β-
testosterone/CYP3A4/min) from three independent experiments. ND, not detected. (B) 
Amounts of ellipticine metabolites generated from free ellipticine (Elli) and ApoElli by human 
CYP3A4 co-expressed with cytochrome b5 in SupersomesTM in the presence of NADPH. 
Values are mean ± SD (pmol 9-hydroxy-, 12-hydroxy and/or 13-
hydroxyellipticine/CYP3A4/min) from three independent in vitro incubations. Control – 
control incubation without NADPH. *** p < 0.001 significant differences between ellipticine 
metabolite formation at pH 7.4 and 6.5 (ANOVA with post-hoc Tukey HSD Test). (C) Amounts 
of ellipticine-derived DNA adduct 1 generated from free ellipticine (Elli) and ApoElli by human 
CYP3A4 co-expressed with cytochrome b5 in SupersomesTM in the presence of NADPH 
determined by 32P-postlabeling. Values are mean ± SD from three independent in vitro 
incubations. Control – control incubation without NADPH. RAL, relative adduct labeling. ***p 
< 0.001 significant differences between ellipticine-DNA adduct formation at pH 7.4 and 6.5; 
ΔΔΔ
 p < 0.001 significant differences between ellipticine-DNA adduct formation by free 
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ellipticine and its ApoElli form (ANOVA with post-hoc Tukey HSD Test). Insert: 
Autoradiographic profiles of DNA adducts generated by free ellipticine (a) and ApoElli (b) in 
the CYP3A4 Supersomal system. Adduct spot 1 is formed in deoxyguanosine residues of DNA 
by the ellipticine metabolite 13-hydroxyellipticine. 
 
Fig. 6. The amounts of ellipticine (nmol) determined in liposomes after its transfer from ApoElli 
into these liposomes and in supernatant containing residual ApoElli (full incubation). In control 
incubation, sediment corresponded to precipitated ApoElli. In this precipitate and the residual 
supernatant the amounts ellipticine was also determined. See experimental conditions for 
details.     
 
Fig. 7. (A) Expression of SCARA5 in neuroblastoma UKF-NB-4 and non-malignant HDFn 
cells. (a) Western blot analysis of SCARA5 expression in UKF-NB-4 and HDFn cells. A 
representative image of the Western blotting is shown; (b) Western blot analysis of GAPDH 
protein expression in UKF-NB-4 and HDFn cells was used as a loading control; (c) Relative 
SCARA5 expression compared with GAPDH in UKF-NB-4 and HDFn cells. (B) Subcellular 
location of ellipticine (Elli) after 2 hours exposure of neuroblastoma UKF-NB-4 and non-
malignant HDFn cells to 10 µM ellipticine and with the same concentration of ellipticine loaded 
apoferritin (ApoElli); 1 – membrane, 2 – nucleus, 3 – cytoplasm. (C) Fluorescence intensities 
(RFU, relative fluorescence units) of ellipticine in the whole cells. (D) Fluorescence intensities 
of ellipticine in cell nuclei. Values are mean ± SD from three independent experiments. ** p < 
0.01 significant differences between fluorescence intensity in UKF-NB-4 and HDFn cells; ΔΔ p 
< 0.01 significant differences between fluorescence intensity in UKF-NB-4 and HDFn cells 
treated with free ellipticine (Elli) and ApoElli (ANOVA with post-hoc Tukey HSD Test). 
 
Fig. 8. (A,B) Cytotoxicity (viable cells as percentage of control) in neuroblastoma UKF-NB-4 
(A) and fibroblastic HDFn (B) cells treated with free ellipticine (Elli) and ApoElli for 48 hour 
determined by the AlamarBlue assay. Values are mean ± SD from three independent 
experiments. (C,D) Apoptosis in neuroblastoma UKF-NB-4 (C) and HDFn (D) cells induced 
by free ellipticine (Elli) and ApoElli. Values are mean ± SD from three independent 
experiments. *** p < 0.001, ** p < 0.01, significant differences between cells treated with free 
ellipticine and its ApoElli form and control (untreated) cells (ANOVA with post-hoc Tukey 
HSD Test). (E,F) Cell cycle distributions in UKF-NB-4 (E) and HDFn (F) cells induced by 
free ellipticine (Elli) and ApoElli. Values are mean ± SD from three independent experiments. 
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*** p < 0.001, ** p < 0.01, * p < 0.05, significant differences between cells treated with free 
ellipticine or ApoElli and control (untreated) cells (ANOVA with post-hoc Tukey HSD Test). 
(G) Haemocompatibility assay of presented nanocarriers using RBC. ApoElli at various 
concentrations (ellipticine concentrations of 0; 6.3; 12.5; 25; 50 and 100 μM) was mixed in 1:1 
volume ratio with washed RBC diluted in PBS and incubated for 1 hour at 37°C. Lysed 
erythrocytes absorbance (540 nm) was measured with evaluated percentage of haemolytic RBC 
with ambient light visualization of the haemolytic RBC.  
 
Fig. 9. Cell index of neuroblastoma UKF-NB-4 cells treated with free ellipticine (Elli) and 
ApoElli. Representative data from one of three independent experiments are shown. 
 
Fig. 10. (A) Analysis of phosphorylated H2AX (γH2AX) in neuroblastoma UKF-NB-4 and 
fibroblastic HDFn cells induced by ellipticine (Elli) and ApoElli. Values are mean ± SD from 
three independent experiments. ** p < 0.01, significant differences between UKF-NB-4 cells 
treated with free ellipticine and ApoElli. ΔΔΔ p < 0.001 significant differences between UKF-
NB-4 and HDFn cells (ANOVA with post-hoc Tukey HSD Test). (B) Ellipticine-derived DNA 
adduct formation in neuroblastoma UKF-NB-4 cells treated with 5 µM ellipticine (Elli) and 5 
µM ApoElli determined by 32P-postlabeling. Values of relative adduct labelling are expressed 
as adducts per 106 normal nucleotides. Values represent mean ± SD from three independent 
experiments. * p < 0.05, significant differences between levels of ellipticine-DNA adducts in 
UKF-NB-4 cells treated with free ellipticine and ApoElli (ANOVA with post-hoc Tukey HSD 
Test). Insert: Autoradiographic profiles DNA adducts formed in UKF-NB-4 cells exposed to 
free ellipticine (a) and ApoElli (b) determined by 32P-postlabeling. Adduct spots 1 and 2 are 
formed in deoxyguanosine residues of DNA by the ellipticine metabolites 13-hydroxy- and 12-
hydroxyellipticine, respectively.  
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